Inhaled liposomal tobramycin - Axentis Pharma AG

Next Previous
Drug Profile

Inhaled liposomal tobramycin - Axentis Pharma AG

Alternative Names: ARB-CF0223; Fluidosome tobramycin; Fluidosomes-tobramycin

Latest Information Update: 07 Aug 2015

Price : $50

At a glance

  • Originator aRigen
  • Developer Axentis Pharma
  • Class Aminoglycosides; Antibacterials; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 07 Aug 2015 Phase-II development is ongoing in Europe
  • 16 Jul 2009 Tobramycin liposomal receives orphan drug status for Cystic fibrosis-associated respiratory tract infections caused by Burkholderia cepacia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top